TCTP as a therapeutic target in melanoma treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Translationally controlled tumor protein (TCTP) is an anti-apoptotic protein implicated in various cancers.
• TCTP overexpression is observed in multiple tumor types, and its silencing can induce tumor reversion.
• There is a known reciprocal repression between TCTP and P53, and sertraline has been shown to decrease TCTP levels.

Purpose of the Study:

• To investigate the role of TCTP in melanoma.
• To evaluate the efficacy of sertraline, an inhibitor of TCTP, in melanoma treatment.
• To assess TCTP as a potential therapeutic target for melanoma.

Main Methods:

• Assessed melanoma cell viability, migration, and clonogenicity in vitro using human and murine melanoma cells with TCTP inhibition via sertraline and siRNA.
• Evaluated sertraline's efficacy in a murine melanoma model.
• Compared sertraline's anti-melanoma effects with dacarbazine, a standard chemotherapy agent.

Main Results:

• Inhibition of TCTP levels significantly reduced melanoma cell viability, migration, clonogenicity, and in vivo tumor growth.
• Sertraline treatment diminished migration and colony formation in human melanoma cells.
• Sertraline demonstrated superior efficacy in inhibiting tumor growth in a murine melanoma model compared to dacarbazine.

Conclusions:

• Sertraline shows potential as an effective therapeutic agent against melanoma.
• Targeting TCTP presents a promising strategy for melanoma therapy.